News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
658,319 Results
Type
Article (59565)
Company Profile (221)
Press Release (598533)
Section
Business (181606)
Career Advice (3057)
Deals (32900)
Drug Delivery (112)
Drug Development (83263)
Employer Resources (171)
FDA (16785)
Job Trends (14932)
News (324906)
Policy (35163)
Tag
Academia (2869)
Alliances (46876)
Alzheimer's disease (1290)
Approvals (16683)
Artificial intelligence (130)
Bankruptcy (297)
Best Places to Work (11660)
Biosimilars (82)
Biotechnology (166)
Breast cancer (115)
Cancer (965)
Cardiovascular disease (84)
Career advice (2574)
Cell therapy (213)
Clinical research (65523)
Collaboration (337)
Compensation (142)
COVID-19 (2747)
Data (870)
Diabetes (149)
Diagnostics (6120)
Drug pricing (101)
Earnings (70003)
Employer resources (151)
Events (98348)
Executive appointments (236)
FDA (17243)
Funding (288)
Gene therapy (164)
GLP-1 (659)
Government (4882)
Healthcare (19251)
Infectious disease (2826)
Inflammatory bowel disease (108)
Interviews (550)
IPO (15894)
Job creations (3581)
Job search strategy (2144)
Layoffs (444)
Legal (7795)
Lung cancer (166)
Manufacturing (165)
Medical device (12880)
Medtech (12885)
Mergers & acquisitions (17056)
Metabolic disorders (423)
Neuroscience (1548)
NextGen Class of 2024 (6802)
Non-profit (4863)
Northern California (1163)
Obesity (250)
Opinion (237)
Patents (98)
People (50389)
Phase I (20092)
Phase II (28585)
Phase III (21793)
Pipeline (213)
Postmarket research (3027)
Preclinical (8678)
Radiopharmaceuticals (253)
Rare diseases (198)
Real estate (5484)
Regulatory (23796)
Research institute (2566)
Resumes & cover letters (517)
Southern California (1032)
Startups (3413)
United States (11265)
Vaccines (610)
Weight loss (207)
Date
Today (222)
Last 7 days (840)
Last 30 days (2920)
Last 365 days (35846)
2024 (30494)
2023 (40400)
2022 (51255)
2021 (55742)
2020 (54431)
2019 (48122)
2018 (36493)
2017 (32575)
2016 (31684)
2015 (36187)
2014 (28509)
2013 (24161)
2012 (25880)
2011 (26484)
2010 (24464)
Location
Africa (966)
Arizona (145)
Asia (40515)
Australia (6845)
California (2588)
Canada (1151)
China (214)
Colorado (112)
Connecticut (120)
Europe (90064)
Florida (390)
Georgia (105)
Illinois (314)
Indiana (162)
Kansas (93)
Maryland (534)
Massachusetts (2138)
Michigan (121)
Minnesota (244)
New Jersey (808)
New York (821)
North Carolina (693)
Northern California (1163)
Ohio (120)
Pennsylvania (691)
South America (1264)
Southern California (1032)
Texas (360)
Washington State (304)
658,319 Results for "national institute on drug abuse".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Gilgamesh Pharmaceuticals Awarded $14 Million National Institute on Drug Abuse Grant to Advance Novel, Cardiac-Safe Ibogaine Analog for the Treatment of Opioid Use Disorder
Gilgamesh Pharmaceuticals today announced that it has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, its novel, cardiac-safe ibogaine analog for the treatment of substance use disorders.
March 14, 2024
·
3 min read
Bio NC
Cessation Therapeutics Awarded $14.8 Million Grant from the National Institute of Drug Abuse to Develop Novel Formulation of Anti-Fentanyl Monoclonal Antibody
Cessation Therapeutics, Inc. today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health).
October 18, 2023
·
4 min read
Pharm Country
Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH’s National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder
Tris Pharma, Inc. announced that the company has been awarded a grant expected to provide up to $16.6M over five years from the National Institute on Drug Abuse, part of the National Institutes of Health.
August 28, 2023
·
4 min read
Press Releases
SciTech Development, Inc. Announces Receipt of Drug Supply From The National Cancer Institute (NCI)
September 18, 2024
·
2 min read
Biotech Bay
MAPS PBC Announces National Institute on Drug Abuse to Share Data for New Drug Application for MDMA-Assisted Therapy for Treatment of PTSD
MAPS Public Benefit Corporation (“MAPS PBC”) announced that the National Institute on Drug Abuse (“NIDA”), part of the National Institutes of Health, has agreed to provide data to supplement the company’s new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for MDMA-assisted therapy as a treatment for post-traumatic stress disorder (“PTSD”).
June 21, 2023
·
5 min read
Business
Macomics and the Institute of Oncology Research (IOR, Switzerland) Announce Macrophage Scientific Collaboration in Prostate Cancer Drug Development
Macomics Ltd, a leader in macrophage drug discovery, announces that it has entered a scientific collaboration with Prof. Andrea Alimonti at IOR, one of Switzerland’s leading research institutes.
June 19, 2024
·
5 min read
Pharm Country
Xylyx Bio Awarded $2.26M NIH SBIR Grant from National Cancer Institute
Xylyx Bio, Inc. announced that it has been awarded a Small Business Innovation Research Fast-Track grant from the National Cancer Institute of the National Institutes of Health to advance commercial development of its InMatrico® disease modeling and drug testing platform to help scientists discover and test drug candidates for metastatic breast cancer.
June 14, 2024
·
2 min read
Biotech Beach
Camino Pharma receives $1.97M Small Business Innovation Research (SBIR) Grant from the National Institute of Alcohol Abuse and Alcoholism
Camino Pharma, LLC announced that its co-founder and CSO, Reto Gadient, Ph.D., has been awarded a two-year, $1.97M grant by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number U43AA031388 and is the Principal Investigator on the grant.
December 7, 2023
·
4 min read
Business
The Foundation for the National Institutes of Health Names Recipients of the 2024 Charles A. Sanders, MD, Partnership Award
The Foundation for the National Institutes of Health will award the 2024 Charles A. Sanders, MD, Partnership Award to the National Institutes of Health’s National Institute of Neurological Disorders and Stroke, AbbVie, and Robert and Sarah Newcomb.
June 18, 2024
·
4 min read
Biotech Beach
$9 million NIH grant advances drug to treat nicotine addiction
Scientists at Camino Pharma, LLC, Sanford Burnham Prebys and University of California San Diego School of Medicine received a $9-million grant from the National Institute on Drug Abuse at the National Institutes of Health.
February 6, 2024
·
5 min read
1 of 65,832
Next